+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type, By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others), By Country and Growth Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 94 Pages
  • August 2024
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5992368
The Asia Pacific T-cell Lymphoma Market would witness market growth of 9.1% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific T-cell Lymphoma Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $276.6 million by 2031. The Japan market is registering a CAGR of 8.4% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 9.8% during (2024 - 2031).



Multidisciplinary supportive care teams address patient needs, including pain management, nutritional support, psychosocial counseling, and symptom control, to improve quality of life. Evaluating novel agents, combination therapies, and treatment modalities is essential for these lymphoma patients to enhance outcomes and broaden therapeutic options. Participation in clinical trials is essential for this purpose.

Adopting and utilizing strategies for managing these lymphomas in healthcare settings are crucial aspects that influence patient outcomes, treatment efficacy, and overall healthcare delivery. Clinical trial data demonstrating efficacy, safety profiles, and comparative effectiveness against existing standards of care often guide the adoption of new treatments in these lymphomas. Consensus guidelines from professional organizations help standardize treatment protocols and support adoption decisions.

The growth of the hospital sector in India leads to the establishment of specialized oncology departments and comprehensive cancer centers across the country. These facilities offer state-of-the-art diagnostic capabilities and multidisciplinary treatment options for these lymphomas, including medical oncology, radiation oncology, and stem cell transplantation. As per the Investment Promotion and Facilitation Agency, in FY21, the hospital sector in India recorded revenue of INR 7.94 trillion and is projected to grow to INR 18.34 trillion by FY27. Presently, the diagnostics sector in India is assessed to be worth $4 billion. The organized sector occupies almost 25% of this segment (15% in laboratories and 10% in radiology). The expansion of the hospital sector facilitates increased access to innovative therapies for these lymphomas in India. This includes the availability of targeted therapies, immunotherapies, and participation in clinical trials investigating novel treatment approaches that can potentially enhance treatment outcomes and patient survival rates. In conclusion, rising hospital sector and high rates of the non-Hodgkin lymphoma is driving the growth of the market.

Based on Type, the market is segmented into Peripheral (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, and Others) and Lymphoblastic. Based on Therapy, the market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

  • Bristol Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd
  • Acrotech Biopharma Inc. (Aurobindo Pharma USA)
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Citius Pharmaceuticals, Inc.
  • Genor Biopharma Co. Ltd.
  • Innate Pharma SA
  • Dizal Pharmaceutical Co. Ltd.

Market Report Segmentation

By Type
  • Peripheral
  • Cutaneous T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Angio-immuno-blastic T-cell Lymphoma
  • Others
  • Lymphoblastic
By Therapy
  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others
By Country
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific T-cell Lymphoma Market, by Type
1.4.2 Asia Pacific T-cell Lymphoma Market, by Therapy
1.4.3 Asia Pacific T-cell Lymphoma Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Asia Pacific T-cell Lymphoma Market by Type
4.1 Asia Pacific Peripheral Market by Country
4.2 Asia Pacific T-cell Lymphoma Market by Peripheral Type
4.2.1 Asia Pacific Cutaneous T-cell Lymphoma Market by Country
4.2.2 Asia Pacific Anaplastic Large Cell Lymphoma Market by Country
4.2.3 Asia Pacific Angio-immuno-blastic T-cell Lymphoma Market by Country
4.2.4 Asia Pacific Others Market by Country
4.3 Asia Pacific Lymphoblastic Market by Country
Chapter 5. Asia Pacific T-cell Lymphoma Market by Therapy
5.1 Asia Pacific Chemotherapy Market by Country
5.2 Asia Pacific Radiotherapy Market by Country
5.3 Asia Pacific Immunotherapy Market by Country
5.4 Asia Pacific Stem Cell Transplantation Market by Country
5.5 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific T-cell Lymphoma Market by Country
6.1 China T-cell Lymphoma Market
6.1.1 China T-cell Lymphoma Market by Type
6.1.1.1 China T-cell Lymphoma Market by Peripheral Type
6.1.2 China T-cell Lymphoma Market by Therapy
6.2 Japan T-cell Lymphoma Market
6.2.1 Japan T-cell Lymphoma Market by Type
6.2.1.1 Japan T-cell Lymphoma Market by Peripheral Type
6.2.2 Japan T-cell Lymphoma Market by Therapy
6.3 India T-cell Lymphoma Market
6.3.1 India T-cell Lymphoma Market by Type
6.3.1.1 India T-cell Lymphoma Market by Peripheral Type
6.3.2 India T-cell Lymphoma Market by Therapy
6.4 South Korea T-cell Lymphoma Market
6.4.1 South Korea T-cell Lymphoma Market by Type
6.4.1.1 South Korea T-cell Lymphoma Market by Peripheral Type
6.4.2 South Korea T-cell Lymphoma Market by Therapy
6.5 Singapore T-cell Lymphoma Market
6.5.1 Singapore T-cell Lymphoma Market by Type
6.5.1.1 Singapore T-cell Lymphoma Market by Peripheral Type
6.5.2 Singapore T-cell Lymphoma Market by Therapy
6.6 Malaysia T-cell Lymphoma Market
6.6.1 Malaysia T-cell Lymphoma Market by Type
6.6.1.1 Malaysia T-cell Lymphoma Market by Peripheral Type
6.6.2 Malaysia T-cell Lymphoma Market by Therapy
6.7 Rest of Asia Pacific T-cell Lymphoma Market
6.7.1 Rest of Asia Pacific T-cell Lymphoma Market by Type
6.7.1.1 Rest of Asia Pacific T-cell Lymphoma Market by Peripheral Type
6.7.2 Rest of Asia Pacific T-cell Lymphoma Market by Therapy
Chapter 7. Company Profiles
7.1 Bristol Myers Squibb Company
7.1.1 Company Overview
7.1.2 SWOT Analysis
7.2 Daiichi Sankyo Company, Limited
7.2.1 Company Overview
7.2.2 SWOT Analysis
7.3 Eisai Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 SWOT Analysis
7.4 Acrotech Biopharma Inc. (Aurobindo Pharma USA)
7.4.1 Company Overview
7.5 Shenzhen Chipscreen Biosciences Co., Ltd.
7.5.1 Company Overview
7.6 Citius Pharmaceuticals, Inc.
7.6.1 Company Overview
7.6.2 Recent strategies and developments:
7.6.2.1 Trials and Approvals:
7.7 Genor Biopharma Co. Ltd
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.8 Innate Pharma SA
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.9 Dizal Pharmaceutical Co. Ltd.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Trials and Approvals:

Companies Mentioned

  • Bristol Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd
  • Acrotech Biopharma Inc. (Aurobindo Pharma USA)
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Citius Pharmaceuticals, Inc.
  • Genor Biopharma Co. Ltd.
  • Innate Pharma SA
  • Dizal Pharmaceutical Co. Ltd.

Methodology

Loading
LOADING...